CDXS
CODEXIS, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.32
+6.45%Year over year
Reported trailing growth
- Revenue
- +35.9%
- EBITDA
- +59.5%
- EBIT
- +57.6%
- EPS
- +59.5%
- Free cash flow
- +82.0%
- Operating cash flow
- +83.0%
Forward estimates
Based on analyst estimates
- Revenue
- +11.1%
- EBITDA
- +6.2%
- EPS
- +9.5%
Three-year CAGR
- Revenue
- -20.2%
- EBITDA
- +36.6%
- EBIT
- +34.5%
- Net income
- +32.6%
- EPS
- +43.8%
- Free cash flow
- +55.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026